Bill Gates’ is about to mint millionaires (again) with Stargate.

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

David Mauro Biography and Net Worth

Insider of Prelude Therapeutics

David Mauro, M.D. currently serves as Chief Medical Officer at Prelude Therapeutics. Dr. Mauro joined Prelude in 2019 and has over 18 years of experience in oncology clinical development. Prior to joining Prelude, he served as Chief Medical Officer at Checkmate Pharmaceuticals Inc. from 2016 until 2019. Prior to Checkmate, Dr. Mauro served as Chief Medical Officer at Advaxis, Inc. from 2014 until 2016, Executive Director at Merck from 2007-2014, and prior to that, as a Director at Bristol Myers Squibb. Dr. Mauro’s experience covers a wide span of oncology drug development including translational, early and late stage development, as well as U.S. medical affairs activities. He participated in three successful NDAs for Erbitux® (cetuximab), Sprycel® (dasatinib), and Sylatron® (peginterferon alfa-2b) as well as EGFR and KRAS companion diagnostics. Dr. Mauro received a B.S. in Biochemistry from Cornell University and an M.D. and Ph.D. from Temple University School of Medicine. He completed residency training at the NIH/NCI in Bethesda.

What is David J. Mauro's net worth?: The estimated net worth of David J. Mauro is at least $15,600.00 as of June 7th, 2021. Dr. Mauro owns 15,000 shares of Prelude Therapeutics stock worth more than $15,600 as of November 16th. This net worth approximation does not reflect any other investments that Dr. Mauro may own. Learn More about David J. Mauro's net worth.
How do I contact David J. Mauro?: The corporate mailing address for Dr. Mauro and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at [email protected]. Learn More on David J. Mauro's contact information.
Has David J. Mauro been buying or selling shares of Prelude Therapeutics?: David J. Mauro has not been actively trading shares of Prelude Therapeutics during the last ninety days. Most recently, David J. Mauro sold 15,000 shares of the business's stock in a transaction on Tuesday, October 5th. The shares were sold at an average price of $30.96, for a transaction totalling $464,400.00. Learn More on David J. Mauro's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes Andrew Combs (EVP), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.

David J. Mauro Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/5/2021	Sell	15,000	$30.96	$464,400.00
9/7/2021	Sell	15,000	$36.69	$550,350.00
8/5/2021	Sell	15,000	$31.09	$466,350.00
7/6/2021	Sell	15,000	$27.47	$412,050.00	15,000
6/7/2021	Sell	15,000	$32.44	$486,600.00	15,000
5/5/2021	Sell	15,000	$40.14	$602,100.00	15,000
4/19/2021	Sell	25,000	$30.89	$772,250.00	25,000

David J. Mauro Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $1.04

$1.00

$1.08

50 Day Range

MA: $2.13

$1.03

$5.38

2 Week Range

Now: $1.04

$1.00

$6.80

Volume

425,323 shs

Average Volume

161,966 shs

Market Capitalization

$57.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56